study question: Which genes and molecular mechanisms are involved in the human ovulatory cascade and final oocyte maturation? summary answer: Up-regulated genes in granulosa cells (GC) represented inflammation, angiogenesis, extracellular matrix, growth factors and genes previously associated with ovarian cancer, while down-regulated genes mainly represented cell cycle and proliferation.
Introduction
The mid-cycle surge of luteinizing hormone (LH) is the physiological trigger of ovulation, while a bolus hCG is the golden standard used in connection with assisted reproduction.
Ovulation essentially induces three distinct and highly complex processes comprising oocyte maturation, ovulation with release of an oocyte and transformation of the avascular granulosa cells (GC) into the highly vascularized granulosa-lutein cells. Rupture of the follicles has been characterized as a local inflammatory process during which the follicle releases the enclosed mature oocyte and subsequently undergoes profound remodeling leading to the formation of a corpus luteum (CL) to support possible implantation. The molecular processes behind the ovulatory cascade have only been studied in humans to a limited extent, because of limited access to follicles immediately before triggering of final oocyte maturation. Although some data are available from animal studies (Park et al., 2004; Espey, 2006; Stocco et al., 2007; Xu et al., 2011; Christenson et al., 2013) , results may not readily extrapolate to humans.
In this study, we describe for the first time a paired analysis of transcriptome changes in GC and hormonal changes in follicular fluid (FF) of the preovulatory follicles before and 36 h after recombinant human chorionic gonadotrophin (rhCG) triggering of final oocyte maturation from the same women in the same cycle following controlled ovarian stimulation (COS).
Materials and Methods
This study was approved by The Danish Scientific Ethical Committee and conducted in accordance with the Helsinki Declaration II. All participants gave informed consent before their inclusion in this study.
Participants
A paired sample of FF before and after rhCG administration was obtained from each of 24 women aged (mean + SD) 27.9 + 3.4 years. Only those women who had developed more than eight follicles of at least 14 mm in diameter at the last control visit before rhCG triggering were enrolled. From 9 of the 24 women GC yielding good quality RNA were obtained prior to and after rhCG triggering (patient demographics and baseline characteristic are shown in Supplementary data, Table SI ). The demographics and baseline characteristics in the nine women who contributed with paired samples of GC did not differ from the 15 women who only contributed paired samples of FF (data not shown).
Controlled ovarian stimulation with exogenous gonadotrophins
The women were treated according to the standard long gonadotrophinreleasing hormone agonist protocol: pituitary desensitization with buserelin 0.5 mg (Suprefact w , Sanofi-Aventis, France) was started on Cycle day 21. COS with recombinant follicle-stimulating hormone (rFSH) (Puregon w , MSD, Denmark) was started after at least 14 days of desensitization. Six thousand five hundred international units rhCG (Ovitrelle w , Merck Serono, Denmark) was administered 36 h before oocyte pick-up (OPU) when at least three follicles had reached the size of 17 mm.
Follicle puncture and isolation of GC
FF and GC were sampled by transvaginal ultrasound guided puncture of a follicle 14-17 mm in diameter at the last control visit before administration of rhCG. Follicle puncture was performed 13 h prior to rhCG administration for 10 women, 37 h for 13 women and 61 h for one woman. For the nine paired samples used for microarray analysis, four follicle punctures were performed at 13 h, four follicle punctures at 37 h and one follicle puncture at 61 h prior to hCG administration.
The puncture was performed with a single lumen needle (Wallace Oocyte Recovery Systems, Smith Medical, Brisbane, Australia) attached to a syringe (10 ml BD Discardit TM II, Becton Dickinson S.A. Fraga, Huesca, Spain) under transvaginal ultrasound guidance. After collection of FF, a new syringe containing flushing medium (Sydney IVF Follicle Flush buffer K-SIFB-100, Cook, Queensland, Australia) was used to flush the follicle if no or few GC aggregates were present in the FF.
During OPU, FF from the first punctured follicle on each ovary was collected separately and used for collection of GC and FF. GC were isolated as described previously (Grøndahl et al., 2012) .
FF analysis
Immediately after GC collection, FF was isolated by centrifugation at 300 g for 10 min. The supernatant was transferred to 2 ml cryotubes and stored at 2808C until analysis. Estrogen, progesterone, androstenedione and testosterone were measured with enzyme-linked immunosorbent assays (NovaTec Immundiagnostica, Dietzenbach, Germany, DNOV 002, 003, 006 and 008, respectively) and performed according to manufacturer's instructions. Anti-Müllerian Hormone (AMH) was measured with AMH ELISA kit (AMH ELISA, AL-105-i Ansh Labs Houston, TX, USA) according to manufacturer's instructions.
Isolation of mRNA
The Absolutely RNA Nanoprep kit from Stratagene (Agilent Technologies, Waldbronn, Germany) was used to isolate total RNA from GC according to the manufacturer''s instructions. The samples were analyzed for total RNA quality and level of degradation using an Agilent 2100 Bioanalyzer and RNA 6000 Pico LabChip according to the manufacturer''s instructions (RNA 6000 Pico assay kit, Agilent Technologies, Waldbronn, Germany). All of the RNA samples showed two distinct peaks representing 18s and 28s rRNA which indicated good quality RNA.
Microarray analysis
Total RNA (ranging from 1.5 -50 ng RNA, mean + SD 27 + 18.9 ng) from each sample was amplified using the Ovation Pico WTA v.2 RNA Amplification System from NuGEN w Inc. (NuGEN w , San Carlos, CA, USA) and biotin labeling was performed with the Encore Biotin Module (NuGEN w ). The labeled samples were hybridized to the Human Gene 1.0 ST GeneChip array (Affymetrix, Santa Clara, CA, USA). The arrays were washed and stained with phycoerythrin conjugated streptavidin (SAPE) using the Affymetrix Fluidics Station w 450, and the arrays were scanned in the Affymetrix GeneArray w 3000 7G scanner to generate fluorescent images, as described in the Affymetrix GeneChip w protocol. Cell intensity files (CEL files) were generated in the GeneChip w Command Console w Software (AGCC) (Affymetrix).
Validation of differential expression by quantitative reverse transcriptase PCR (qRT-PCR)
The following genes were tested by pre-designed TaqMan w Gene Expression Assays (gene symbol/catalogue number):
Hs00996788_m1) and INHBA (Hs01081598_m1) as well as the Endogenous Control Assays for human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Applied Biosystems/Life Technologies Europe, Naerum, Denmark). The data were normalized to GAPDH, and relative quantification according to the comparative cycle threshold (CT) Method (LightCycler480 Software, Roche, Denmark) was used to quantify gene expression. GAPDH was chosen as reference gene based on stable expression in GC over various follicle classes (Kristensen et al., 2013) . Average cycle threshold (Ct) values for GAPDH (mean + SD) were 21 + 1.2 and 22 + 1.4 before and after rhCG, respectively.
Statistical analysis
Differences in hormone concentration before and after rhCG were tested by Wilcoxon matched-pairs signed rank test. Differences in qRT-PCR gene expression between paired samples of GC were calculated by ratio paired t-test (GraphPad Prism versus 6, GraphPad Software, San Diego, CA, USA).
Differential gene expression analysis
For statistical analysis the CEL files (nine representing GC before rhCG and nine representing GC 36 h after rhCG) were imported into the R (www. r-project.org/ (27 January 2014, date last accessed).) where they were robust multichip averaged (RMA) using quantile normalization and Median Polish summarization (Bolstad et al., 2003) . The expression profiles in the two conditions were compared and genes were defined as differentially expressed when they were selected in the paired t-test, having P-values below 0.0001 and fold-change .2.
All samples are minimum information about a microarray experiment (MIAME) compliant and were handled according to standard operation procedures in the Microarray Center. The 18 arrays were submitted to ArrayExpress at EMBL using MAGE-TAB submission. The accession number is E-MTAB-2203.
Gene function and pathway enrichment analysis
The list of differentially expressed genes were subjected to gene function enrichment and pathway analysis in the Ingenuity w software (www. ingenuity.com (27 January 2014, date last accessed)) as described in Grøn-dahl et al. (2010 Grøn-dahl et al. ( , 2013 . Furthermore, an upstream regulator analysis (Ingenuity w Systems) was performed to reveal potential regulators of the observed effect of the rhCG triggering.
Validation of differential expression by external macaque ovulation data set
The dataset GSE22776 was downloaded from http://www.ncbi.nlm.nih.gov/ geo/ (27 January 2014, date last accessed). The data set contains 22 samples from Macaque periovulatory follicles of which 10 samples were used in this study. These files are: GSM563219.CELGSM563220.CEL-GSM563221. CEL-GSM563222.CEL-GSM563223.CEL-GSM563224.CEL-GSM563233.CE-L-GSM563234.CEL-GSM563235.CEL-GSM563236.CEL, representing follicles before and 36 h after exposure to an ovulatory rhCG dose.
The CEL files were imported into R and RMA normalized. The expression matrix was exported to dChip (www.dchip.org (27 January 2014, date last accessed)) and used as basis of cluster visualization of genes, which were found to be differentially expressed in our data.
Two thousand and seventy-nine redundant Macaque probe sets (a particular gene was represented more than once in the gene list) were overlapping between the Macaque Gene arrays and the present Human Gene arrays, based on the gene symbol of the 1186 unique genes that were defined as differentially expressed. This gene list was filtered to exclude genes (probe sets) in the primate data that showed only a small relative variation across samples (0.05 ,SD/mean ,1000.00). The 786 overlapping probe sets (513 unique genes) that were left after the filtering were used in a two-way hierarchical cluster visualization using the Qlucore Omics Explorer version 2.3 software (www.glucore.com) with average linkage (Supplementary data, Table SII).
Results

Differentially expressed genes
Unsupervised principal component analysis (PCA) revealed that the samples clustered within each of the two time frames and demonstrated general difference in the transcriptome in the GC before and after rhCG triggering (Fig. 1A) .
Setting the criteria for being differentially expressed in the paired t-test to P , 0.0001 (false discovery rate (FDR): 0.0012) and a fold change exceeding 2, a total of 1224 probe sets (1186 unique genes) were found to be differentially expressed with 572 genes being up-regulated and 614 genes down-regulated in the two types of GC (cluster diagram in Fig. 1B) . Table I 
Confirmation of array data by qRT-PCR analysis of selected genes
qRT-PCR of 11 selected genes in 7 paired samples of GC before/after rhCG demonstrated agreement with the microarray data (Fig. 2) .
Human granulosa cell transcriptome and ovulation
Comparison with macaque whole follicle database before and 36 h after rhCG
To examine the relevance of the present data to events in a natural cycle, the 1186 significantly differentially expressed genes reported in this paper were compared with the gene set generated by Xu et al. (2011) from macaques in their natural cycle before and 36 h after hCG triggering. This revealed that the macaque data included 786 overlapping probes (513 unique genes) with a differential expression pattern before and after rhCG, which resembled the expression pattern detected in our human data ( Fig. 3 and Supplementary data, Table SII) .
Gene function enrichment analysis
The top 'Molecular and Cellular Function' and the top 'Disease and Disorder' enriched in the differentially expressed genes were Cell Cycle (P ¼ 1.7E225; 132 genes) and Cancer (P ¼ 1.5E225; 435 genes), respectively. Seventy-two genes previously described in connection with ovarian cancer were among the highly regulated genes according to the Ingenuity w enrichment analysis (Supplementary data, Table SIV ). Expression of cell cycle-related genes was highly down-regulated 36 h after the bolus of rhCG while inflammation and coagulation related genes were highly up-regulated after rhCG. The 'Top Canonical Pathway analysis' listed in Table II likewise underlined these central mechanisms represented in the up-and down-regulated genes.
In the following sections, the results are highlighted with special emphasis on ovarian physiology and new genes in reproduction. For a brief overview, please refer to Fig. 4 .
New ovulation-related genes in humans
Many of the highly regulated genes were previously unrelated to ovulation, such as, for example, the highly up-regulated CD24 (CD24 protein), ANKDR22 (ankyrin repeat domain 22), TECRL (trans-2,3-enoyl-CoA reductase-like), FBXO32 (F-box protein 32), FLRT2 (fibronectin leucine rich transmembrane protein 2), CLDN11 (claudin 11) and the highly downregulated CEP55 (Centrosomal protein 55 kDa) and H19/mir675 (micro-RNA 675) ( Table I) .
Steroidogenesis and gonadotrophin receptors
The FF hormone concentrations before and after rhCG triggering are listed in Table III . The FF estrogen concentration decreased significantly after rhCG with a concomitant decrease in CYP19A1 (cytochrome P450, family 19, subfamily A, polypeptide 1) expression. The FF androstenedione concentration decreased significantly after rhCG, accompanied by a decrease in the expression of the theca cell-specific CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1). The FF progesterone concentration and StAR expression (P ¼ 0.00031, fold change 2.7) increased after rhCG as expected, while at time points before and 36 h after rhCG, gene expression of genes promoting progesterone synthesis HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta-and steroid delta-isomerase 2), LDLR (low density lipoprotein receptor) and CYP11A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) were unaltered. Testosterone concentrations before and after rhCG were unaltered as was HSD17B (17b-hydroxysteroid dehydrogenase) expression.
Figure 1 (A) Unsupervised PCA of human GC before and after rhCG triggering demonstrated general difference in the transcriptome before and after rhCG triggering. Blue labels represent GC samples before rhCG and red labels represent samples after rhCG. The single outlier among the 'before rhCG' sample did not differ according to baseline descriptive parameters in any way and the follicle puncture was performed 13 h prior to rhCG, but the amplified amount of RNA was only 1.5 ng, which was low compared with the other samples. This might explain why this sample behaved as an outlier (see Materials and methods for details). Horizontal axis corresponds to principal component 1 (PC1), vertical axis corresponds to PC2 and depth axis corresponds to PC3. The percent of variation explained by a particular PC is indicated in the axis label. (B) Hierarchical cluster diagram showing the 1186 genes selected as being differentially expressed between human GC before and after rhCG triggering (P , 0.0001 and fold change .2). The expression level for each gene is standardized to have a mean value of zero and a SD of 1. Black color represents the mean value zero, red color represents the gene expression level above the mean and green color represents expression below the mean. The intensity of the pseudo-color reflects the number of SDs from the mean. Continued HSD11B1 (hydroxysteroid 11b dehydrogenase 1) was up-regulated while HSD11B2 (Hydroxysteroid 11b dehydrogenase 2) was downregulated. The expression of FSHR (follicle-stimulating hormone receptor) and LHCGR (luteinizing hormone receptor) decreased after rhCG, as did INHBA (inhibin bA) (Table I ).
Exit from cell cycle
Cyclins were down-regulated concomitantly with an increase in cell cycle inhibitors (CDKN1A, alias p21 cip , cyclin-dependent kinase inhibitor 1A). Other genes marking actively dividing cells, such as TOP2A (topoisomerase 2 alpha), CDC20 (cell division cycle 20) and the MCM's (minichromosome maintenance complex components) were dramatically down-regulated (Table I and Supplementary data, Table SIII ).
Inflammation, angiogenesis and coagulation
Many inflammation-related genes were highly up-regulated after rhCG, such as genes involved in prostaglandin synthesis: PTSG2 (prostaglandin endoperoxide synthase 2), PTGES (prostaglandin E synthase), PLA2G4A (phospholipase A2, group 4A) and the leukotriene-producing enzymes from the lipoxygenase pathway ALOX5 (arachidonate 5 lipoxygenase) and ALOX5AP (arachidonate 5-lipoxygenase-activating protein) (Table I and Supplementary data, Table SIII ) Genes involved in interleukin signaling and acute phase response were also highly represented among the up-regulated genes (Table II) .
Genes promoting angiogenesis and invasiveness, such as CD24 and EFNB3 (ephrin B3), were among the highly up-regulated genes. ANGPT1 (angiopoietin 1) was also up-regulated while VEGFA (vascular endothelial growth factor A) was down-regulated (Table I) . Further, genes involved with coagulation, such as F3 (coagulation factor III) and F2R (coagulation factor II receptor), were up-regulated (Table I) .
Extracellular matrix remodeling and cell-to-cell contact Extracellular matrix protein genes such as HAS2 (hyaluron synthase 2), PTX3 (pentraxin 3), FN1 (fibronectin 1), ADAMTS1 and ADAMTS9 (ADAM metallopeptidase with thrombospondin type 1 motif, 1 and 9) were highly up-regulated (Table I) . MMP19 (matrix metallopeptidase) and TIMP1 (TIMP metallopeptidase inhibitor 1) were up-regulated while TIMP3 were highly down-regulated. COL6A3 (collagen 6A3), FLRT2 (fibronectin leucine rich transmembrane protein 2) and CLDN11 (claudin 11), previously unrelated to ovulation, were highly increased.
Growth factors
The genes encoding the EGF-like ligands AREG (amphiregulin) and EREG (epiregulin) were highly up-regulated after rhCG as was TGF-b1 (transforming growth factor b1). FF AMH concentration decreased significantly (Table III) while AMH gene expression remained unchanged and AMHR2 (anti-Müllerian hormone receptor II) expression decreased 3.7-fold (Table I) . IGF2 (insulin-like growth factor 2) and its genomic neighbor H19/mir675 (microRNA 675) were significantly downregulated after rhCG (Table I) .
Transcription factors and upstream regulators
EGR1 and EGR2 (early growth response) were highly induced by rhCG as was JUN (jun proto-oncogene) and c-FOS (FBJ murine osteosarcoma viral oncogene homolog). FOXL2 (forkhead box L2) was significantly downregulated (Table I) . The in silico upstream regulator analysis suggested FSH, LH as well as PGR (progesterone receptor), ESR1 (estrogen receptor 1) and AR (androgen receptor) as top upstream regulators of the rhCG trigger induced changes. Furthermore, various pro-inflammatory cytokines (i.e. TNF (tumor necrosis factor), IL6 (interleukin-6)), growth factors (i.e. IGF1, IGF2 (insulin-like growth factors 1 and 2), EGF (epidermal growth factor), PGDF b (platelet-derived growth factor b) as well as cell cycle regulators (i.e. CCND1 (cyclin D1), CDKN1A (cyclindependent kinase inhibitor 1A) and transcription factors (i.e. TP53, TP63 (tumor protein 53/63) and FOXO3 (Forkhead box O3) were suggested as top upstream regulators (Table IV and for the full list  Supplementary data, Table SV) .
Discussion
This human transcriptome dataset will serve as an easily accessible source for the study of ovulation-related genes in humans. A unique and highly significant difference was demonstrated in human GC expressed genes obtained from the same women in the same cycle in two hallmarks of folliculogenesis: before and after the ovulatory surge of rhCG for final oocyte maturation. A total of 1186 genes were highly significantly differentially expressed, among those were many genes previously not related to ovulation and interestingly, several of those are reported as related to cancer.
The criteria for differential expression were strict (FC . 2, P , 0.0001, FDR , 0.012); hence, some important ovulation-related genes might have been overlooked. However, our approach in this study was to describe the most significantly differentially expressed ovulation-related genes and pathways.
In addition to qRT-PCR confirmation, our data and model were further validated by a high overlap to differently expressed genes observed in whole follicles from macaque monkeys collected at the same time points as in our study (Xu et al., 2011) . The monkeys were in their natural menstrual cycle and the high overlap may indicate that the data obtained in the present study also represent changes occurring in natural ovulation in humans. This overlap is an important external validation of the data set since the aspiration of a follicle prior to hCG injection hypothetically could induce the formation of an early CL with local and systemic effects potentially influencing the GC transcriptome at 36 h after hCG.
In the following sections, the data will be discussed in the context of known ovarian physiology as well as extended in light of the many new ovulation-related genes found in this study. expressed in human GC before and 36 h after rhCG and genes differentially expressed in the natural cycle in macaque whole follicles at time 0 and 36 h after rhCG triggering (Xu et al., 2011 ). An overlap of 786 genes was revealed, shown here as a hierarchical cluster diagram of the overlapping differentially expressed genes. Purple corresponded to a macaque follicle sample before hCG and orange corresponded to an unruptured macaque follicle sample 36 h after hCG. Black color represents the mean value zero, red color represents the gene expression level above the mean and green color represents expression below the mean. The intensity of the pseudo-color reflects the number of SDs from the mean. GC, granulosa cells.
Steroidogenesis and gonadotrophin receptors
To the best of our knowledge this study is the first to show concentrations of steroids in follicles from the same women collected just prior to and 36 h after ovulation induction. This provided detailed information on the profound changes that occurred in steroidogenesis in connection with ovulation and the hormonal profile of the FFs supported the gene expression data. The expression of CYP17A1 and NR5A1 (nuclear receptor subfamily 5, group A, member 1) indicated minor theca cell contamination, which, however, did not seem to affect the overall results of this study confirming recent bovine data on minor theca cell contamination of GC preparations from follicle aspirates (Christenson et al., 2013) . As in humans, macaques ovulate around 36 h after hCG administration. In macaque whole follicles, an increase in StAR and HSD3B2 was found 12 h after hCG induced ovulation, but decreased to pre-hCG levels 36 h after hCG in non-ruptured follicles and increased again in ruptured follicles, revealing a biphasic pattern of the gene expression of the progestogenic pathway (Xu et al., 2011) . As we found unaltered levels of HSD3B2, LDLR (low density lipoprotein receptor), CYP11A1 36 h after ovulation but increased levels of progesterone in FF, we speculate that in humans there could be a similar biphasic expression pattern of the progestogenic pathway in the periovulatory interval. The early increase of the progestogenic pathway could be important for locally induced actions of progesterone in the follicle whereas the later increase after follicle rupture facilitates CL formation and progesterone production for systemic as well as local purposes (Xu et al., 2011) . Additional radical changes in steroidogenesis occur during the periovulatory period. The decrease of CYP171 (catalyzing androgen production) and CYP19A (converting androstenedione to estrogen) accompanied FF hormone changes and reflected the shift from estrogenic to progestogenic follicles after rhCG.
The opposite expression patterns of HSD11B1 (up-regulation; promoting cortisol production from cortisone) and HSD11B2 (downregulation, promoting cortisone production from cortisol) confirmed previous findings in humans (Yding Andersen et al., 1999) and in macaque whole follicles (Fru et al., 2006) . The very high concentration of biologically active cortisol in FF may serve to attenuate the local inflammatory reaction in the pre-ovulatory follicle preparing for ovulation (Andersen, 2002 Human granulosa cell transcriptome and ovulation
The decreased expression of FSHR and LHCGR was expected (Xu et al., 2011; Jeppesen et al., 2012) and probably reflected receptor downregulation (Hirsh et al., 2005) .
Exit from cell cycle
The LH/hCG surge induces down-regulation of cell cycle genes, in order to decrease GC proliferation and promote final GC differentiation (Stocco et al., 2007) . Down-regulation of cell cycle genes and proliferation marker genes as CDC20, TOP2A and the MCM's were in line with a previous report showing a decline of macaque GC entering S-phase 24 h after rhCG (Fru et al., 2007) and inhibition of GC mitosis in macaque ovaries by a bolus of rhCG (Chaffin et al., 2001) . Additionally, expression of cell cycle inhibitor genes as CDKN1A was increased after rhCG as reported in rodents (Stocco et al., 2007) and macaques (Chaffin et al., 2001) . In macaques, CDKN1A increased early (12 h) after the ovulatory trigger whereas CDKN1B expression increased later (at 36 h) (Chaffin et al., 2001) . CDKN1B expression was also dominant in rodent corpora lutea (Stocco et al., 2007) . This suggested that CDKN1A is important for the initial decline in GC mitosis while CDKN1B might maintain cell cycle arrest in the luteinized cells of the CL. This could explain why we only observed an up-regulation of CDKN1A.
Inflammation
In line with ovulation being compared with an acute inflammatory reaction in the ovary (Espey, 2006) we demonstrated an up-regulation of genes involved in inflammation, such as immune cell trafficking, interleukin-signaling, TNFa activation and prostaglandin synthesis. In primates, prostaglandins are critical for ovulation, but not for luteinisation (Duffy and Stouffer, 2002) . In the present data set, PTGS2 was found to be heavily up-regulated (.13-fold). The specific PTGS2 inhibitor celecoxib has been shown to increase the incidence of delayed rupture of follicles and unruptured follicles in humans, but not as effectively as in monkeys, suggesting that in humans, there are other pathways ensuring follicle rupture (Duffy and Stouffer, 2002) . In humans, the lipoxygenase pathway could, as for other species (Downey et al., 1998; Mikuni et al., 1998 ) play a role in ovulation as well, as we found an up-regulation of ALOX5 and ALOX5AP after rhCG, but this remains to be further investigated.
The increased expression of coagulation factors (F2R, F3), promoting coagulation in the microvasculature, extended previous findings in mice of increased F3 expression shortly after hCG triggering (Carletti and Christenson, 2009 ). The coagulation factors might prevent microbleeding during ovulation.
Angiogenesis and cancer-related genes
More than 400 of the differentially expressed genes were connected to cancer in the biofunction enrichment analysis suggesting that CL formation is an example of a normal physiological process with gene expression similarities to tumor formation without leading to cancer in the right environment. Vasculogenesis and endothelial cell migration functions were highly enriched in the genes up-regulated after rhCG suggesting a A positive z-score indicated activation and a negative z-score indicated inhibition.
shift towards an invasive phenotype. EFNB2 (up-regulated .15-fold in GC 36 h after rhCG) and other ephrins were previously reported to be expressed in human luteinized GC (Xu et al., 2006) . Blocking EFNB2 with highly specific antibodies inhibited angiogenesis, lymphangiogenesis and tumor growth in a xenografted mice model (Abéngozar et al., 2012) . Thus, ephrins may be important for the induction of angiogenesis in the developing CL in humans. The reduced VEGFA (vascular endothelial growth factor A) expression could resemble the pattern of VEGFA expression in the primate periovulatory follicle, with a temporary decrease in expression after hCG followed by a rise after follicle rupture (Xu et al., 2011) . Many ovulation-related genes have previously been associated with cancer and ovarian cancer. This suggests that some forms of ovarian cancer could originate from ovulatory molecular processes that have gone astray, supported by the fact that ovarian epithelial tumors developed and maintained a milieu rich in pro-inflammatory chemokines and cytokines (reviewed in Macciò and Madeddu, 2012) which resembled the local inflammatory reaction in the follicle during ovulation. CD24 expression in ovarian cancer was related to tumor aggressiveness, especially cell invasion and chemotactic migration (Kang et al., 2013) . The massive up-regulation of CD24 expression following rhCG exposure was new and unexpected. It enforces an association between CD24, vascularization and angiogenesis characterizing CL formation. The present observation calls for further investigations to determine the precise role of CD24 in these processes. CLDN11, highly up-regulated by rhCG and not previously related to ovulation, was overexpressed in ovarian cancer, promoting cancer cell invasion (Aravindakshan et al., 2006 (mice) ; English and Santin, 2013) .
TGF-b1 has been proposed as a local regulator of microvascular angiogenesis (Maroni and Davis, 2011) and has also been proposed as a facilitator of CL formation in pigs (Sriperumbudur et al., 2010) . Interestingly, ovarian epithelial cancer cell lines have shown to be refractory to TGF-b1 signaling through loss of expression of TGF-b1/SMAD4 targets FBXO32 and RUNX1 T (Chou et al., 2010) . FBXO32 was among the highly up-regulated genes described here for the first time as being involved in human ovulation. Hence, TGF-b1 and its target genes could serve as a control mechanism of the invasive process of CL formation.
An activating FOXL2 mutation has been described in adult ovarian epithelial tumors (Kö bel et al., 2009) , and besides the target genes StAR and CYP19A1, FOXL2 has pleiotropic effects in TGF-b/SMAD signaling. The down-regulation of FOXL2 36 h after rhCG further underlined the tightly regulated ovulation process.
Extracellular matrix remodeling and cell to cell contact
An abundance of proteases have been implicated in ovulation, such as the Matrix metalloproteinases (MMPs), Tissue inhibitor of metalloproteinase (TIMPs), A Disintegrin And Metalloproteinase with Trombospondin Motifs (ADAMTSs), serine proteases and cathepsin L. ADAMTS1 has been shown to play a central role in human ovulation (Yung et al., 2010) . Here, we report for the first time that ADAMTS9 is also massively induced by rhCG in human GC, in line with findings in macaque (Peluffo et al., 2011) . ADAMTS1, cathepsin L, MMP-1 and TIMP-1 are up-regulated by progesterone in the primate ovary (Chaffin, 1999) . We found MMP5 and TIMP1 to be up-regulated while TIMP3 was down-regulated, underlining the complexity and species differences of the process.
Other extracellular matrix genes that were highly up-regulated after the ovulatory surge, such as COL6A3 have previously been reported in human theca cells (Iwahashi et al., 2000) and in murine cumulus cells and GC in response to rhCG (Adriaenssens et al., 2009) . We have shown for the first time in human GC that COL6A3 expression increased massively after the ovulatory surge. COL6A3 could be an important factor in the ovulatory process and in CL formation.
ANKRD22, coding for a membrane integrated protein ankyrin repeat domain 22 with no known biological function, was highly up-regulated in the post-rhCG GC. A recent comparison of the transcriptome of corresponding cumulus and GC on individual preovulatory follicle level found ANKRD22 expression to be low in cumulus cells, while up to 17-fold higher expressed in GC (Grøndahl et al., 2012) . This indicates a specialized, yet unknown function in the GC-compartment.
Growth factors
Epidermal growth factor (EGF)-family members are induced by LH/hCG and propagate the LH/hCG stimulus in a autocrine and paracrine manner (Conti et al., 2006) . Both AREG (amphiregulin) and EREG (epiregulin) expression was highly increased after rhCG, as expected (Zamah et al., 2010) . INHBA (Inhibin bA) was significantly reduced, extending the findings of Hua et al., (2008) who found decreased INHBA in response to hCG in murine follicles cultured in vitro.
The insulin-like growth factors (IGF1 and 2) are important intra-ovarian growth factors. IGF2 enhances FSH-induced GC proliferation and steroidogenesis (Mazerbourg et al. 2003) . IGF2 and the genomic neighbor H19/mir675 were substantially reduced 36 h after rhCG administration in the present study, confirming previous findings in primate ovary of reduced Igf2 expression after hCG (Brogan et al. 2010) . IGF2-H19 is a tandem gene, whose dual expression is regulated by imprinting: IGF2 is a growth-promoting peptide while H19/mir675 gives rise to several non-coding microRNAs that inhibit cell proliferation (Ratajczak, 2012) . H19/mir675 was previously shown to reduce Igf1 receptor mRNA (Keniry et al. 2012) , and interestingly, IGF1R was increased 1.4 times (P ¼ 0.0005) in the present study. The dramatic downregulation of H19/mir675 after rhCG suggests that H19/mir675 regulation plays an important role during ovulation that remains to be further elucidated.
The role of AMH in the late phases of folliculogenesis remains unsettled . The decrease in AMHR2 expression confirmed the effect of final maturation in human cumulus-oocyte complexes with lower AMHR2 expression in cumulus cells from expanded versus non-expanded cumulus cells (Grøndahl et al., 2011) and lower AMHR2 expression after hCG in rat cumulus-oocyte complexes (Agca et al., 2012) . Higher FF AMH at oocyte retrieval has been linked to decreased pregnancy chance after in vitro fertilisation (Desforges-Bullet et al., 2010) , suggesting that reduced AMH signaling is important for final follicular maturation. Our findings of decreased AMH in FF after rhCG support recent findings of decreased serum AMH levels through the periovulatory interval and the luteal phase (Hadlow et al., 2013) .
Oocyte competence marker genes are found in the follicular to luteal transition expression profile Several of the genes differentially expressed, before and after rhCG, have been suggested as follicular health markers. Hamel et al. (2010) performed three consecutive gene expression studies using GC obtained in connection with OPU, comparing GC from follicles yielding oocytes that resulted in live birth versus GC from follicles resulting in no pregnancy. Interestingly, four of the nine proposed follicle health markers overlapped with our gene set of differentially expressed genes before and after rhCG (RGS2, CYP19A1, UGP2 (UDP-glucose pyrophosphorylase 2) and PHLDA1 (pleckstrin homology-like domain, family A, member 1)). Furthermore, we observed an overlap of our differentially expressed genes and reported cumulus cell marker genes: EFNB2 (Wathlet et al., 2012) , PTGS2, PTX3, HAS2 (Gebhardt et al., 2011) , RGS2, ANKRD22 and PLIN2 (perilipin 2) (Feuerstein et al., 2012) .
This overlap underlined the importance of the final maturational process induced by hCG/LH and downstream signals for the competence of the oocyte to undertake further development, and indicated that ovulation-related genes may serve as good markers of follicle and oocyte quality.
Conclusion
One thousand one hundred and eighty-six genes were significantly differentially expressed when comparing GC isolated before and 36 h after rhCG administration and GC from these two hallmarks of folliculogenesis represent highly distinct gene expression profiles. Known ovulationrelated genes were confirmed and many new ovulation-related genes were discovered, such as CD24, FBXO32, ANKRD22, CLDN11 and H19/mir675.
Up-regulated genes represented inflammation, angiogenesis, extracellular matrix and growth factors. Down-regulated genes represented cell cycle and proliferation. Seventy-two of the regulated genes had previously been related to ovarian cancer. FF hormone analyses confirmed the shift from estrogenic to progestogenic and further, a significant decrease in FF AMH after rhCG was documented.
These data will serve as an easily accessible resource of GC genes involved in human ovulation and final oocyte maturation. The identification of enriched genes, pathways and intermediate regulators of the final follicle maturation is essential for understanding the complicated ovulatory process in more detail and the function of all the individual components involved.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
